# A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

> **NCT05098938** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 2020 (actual)

## Conditions studied

- Recurrent Herpes Labialis

## Interventions

- **DRUG:** Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05098938
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-23
- **Primary completion:** 2023-07-19
- **Final completion:** 2024-07-02
- **Target enrollment:** 2020 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098938, "A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05098938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*